Literature DB >> 30179654

Diversity in the T cell response to Chlamydia-sum are better than one.

Jasmine C Labuda1, Stephen J McSorley2.   

Abstract

Chlamydia trachomatis is responsible for an increasing number of sexually transmitted infections in the United States and is a common cause of serious pathology in the female reproductive tract (FRT). Given the impact and incidence of these infections, the production of an effective Chlamydia vaccine is a public health priority. Mouse models of Chlamydia infection have been utilized to develop a detailed and mechanistic understanding of protective immunity in the FRT. These studies reveal that MHC class-II restricted Chlamydia-specific CD4 T cells are critical for primary bacterial clearance and provide effective protection against secondary infection in the FRT. Despite the clear importance of IFN- γ produced by CD4 Th1 cells, there are also suggestions of wider functional heterogeneity in the CD4 T cell response to Chlamydia infection. Understanding the role of this diversity in the CD4 T helper cell response in the FRT should allow a more nuanced view of CD4 T cell biology in the context of Chlamydia infection and may be critical for vaccine development. Here, we summarize our current understanding of CD4 T helper subsets in the clearance of Chlamydia and discuss some areas where knowledge needs to be further extended by additional experimentation.
Copyright © 2018 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD4 T cells; Chlamydia; T helper subsets

Mesh:

Substances:

Year:  2018        PMID: 30179654      PMCID: PMC6310219          DOI: 10.1016/j.imlet.2018.08.002

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  70 in total

1.  The arrested immunity hypothesis and the epidemiology of chlamydia control.

Authors:  Robert C Brunham; Michael L Rekart
Journal:  Sex Transm Dis       Date:  2008-01       Impact factor: 2.830

2.  A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection.

Authors:  Sandra G Morrison; Richard P Morrison
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

3.  Protective role of serum antibody in immunity to chlamydial genital infection.

Authors:  R G Rank; B E Batteiger
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

4.  CD4⁺CD25⁺Foxp3⁺ regulatory T cells promote Th17 responses and genital tract inflammation upon intracellular Chlamydia muridarum infection.

Authors:  Jessica M Moore-Connors; Robert Fraser; Scott A Halperin; Jun Wang
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

5.  The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4+ T cells.

Authors:  Yasutaka Motomura; Hiroshi Kitamura; Atsushi Hijikata; Yuko Matsunaga; Koichiro Matsumoto; Hiromasa Inoue; Koji Atarashi; Shohei Hori; Hiroshi Watarai; Jinfang Zhu; Masaru Taniguchi; Masato Kubo
Journal:  Nat Immunol       Date:  2011-04-03       Impact factor: 25.606

6.  VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells.

Authors:  Georg Stary; Andrew Olive; Aleksandar F Radovic-Moreno; David Gondek; David Alvarez; Pamela A Basto; Mario Perro; Vladimir D Vrbanac; Andrew M Tager; Jinjun Shi; Jeremy A Yethon; Omid C Farokhzad; Robert Langer; Michael N Starnbach; Ulrich H von Andrian
Journal:  Science       Date:  2015-06-19       Impact factor: 47.728

7.  Human leukocyte antigen and cytokine gene variants as predictors of recurrent Chlamydia trachomatis infection in high-risk adolescents.

Authors:  Chengbin Wang; Jianming Tang; William M Geisler; Peggy A Crowley-Nowick; Craig M Wilson; Richard A Kaslow
Journal:  J Infect Dis       Date:  2005-02-25       Impact factor: 5.226

8.  Eosinophils express functional IL-13 in eosinophilic inflammatory diseases.

Authors:  Peter Schmid-Grendelmeier; Frank Altznauer; Barbra Fischer; Christian Bizer; Alex Straumann; Günter Menz; Kurt Blaser; Brunello Wüthrich; Hans-Uwe Simon
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

9.  The duration of Chlamydia muridarum genital tract infection and associated chronic pathological changes are reduced in IL-17 knockout mice but protection is not increased further by immunization.

Authors:  Dean W Andrew; Melanie Cochrane; Justin H Schripsema; Kyle H Ramsey; Samantha J Dando; Connor P O'Meara; Peter Timms; Kenneth W Beagley
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

Review 10.  Collateral Damage: Detrimental Effect of Antibiotics on the Development of Protective Immune Memory.

Authors:  Joseph M Benoun; Jasmine C Labuda; Stephen J McSorley
Journal:  MBio       Date:  2016-12-20       Impact factor: 7.867

View more
  4 in total

1.  Antibody, but not B-cell-dependent antigen presentation, plays an essential role in preventing Chlamydia systemic dissemination in mice.

Authors:  Priyangi A Malaviarachchi; Miguel A B Mercado; Stephen J McSorley; Lin-Xi Li
Journal:  Eur J Immunol       Date:  2020-03-12       Impact factor: 5.532

2.  Innate IFN-γ Is Essential for Systemic Chlamydia muridarum Control in Mice, While CD4 T Cell-Dependent IFN-γ Production Is Highly Redundant in the Female Reproductive Tract.

Authors:  Miguel A B Mercado; Wuying Du; Priyangi A Malaviarachchi; Jessica I Gann; Lin-Xi Li
Journal:  Infect Immun       Date:  2021-02-16       Impact factor: 3.441

Review 3.  A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections.

Authors:  Abisola Abisoye-Ogunniyan; Isabella M Carrano; Dina R Weilhammer; Sean F Gilmore; Nicholas O Fischer; Sukumar Pal; Luis M de la Maza; Matthew A Coleman; Amy Rasley
Journal:  Front Pharmacol       Date:  2021-11-24       Impact factor: 5.988

4.  Th1 cells are dispensable for primary clearance of Chlamydia from the female reproductive tract of mice.

Authors:  Jordan A Rixon; Claire E Depew; Stephen J McSorley
Journal:  PLoS Pathog       Date:  2022-02-23       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.